Mizolastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C24H25FN6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 244O1F90NA, chemically known as 4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)- but generally known as mizolastine, which bears US NIH Compound Identifier 65906. European Medicines Agency schedules Mizolastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09018MIG. The term MIZOLASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). World Health Organization schedules mizolastine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule mizolastine under HS 29335995 and SITC 51576. As of Q4 2014, MIZOLASTINE remains the US FDA Preferred Term for this commodity. Mizolastine bears US NLM identifiers UMLS ID C0171302 and NCI Concept Code C66171. SMILES: FC1CCC(CN2C(N3CCC(N(C)C4[NH]C(=O)CCN4)CC3)NC3C2CCCC3)CC1.